“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande, the Stanford professor who built a16z's bio practice into a nearly $4 billion fund, has launched a new firm, VZVC, with a fundamentally different approach. In a sharp pivot from the high-volume venture model, Pande and co-founder Zach Werner are making only a handful of concentrated bets per year, signaling a belief that deep, hands-on partnerships are more critical than portfolio size in the capital-intensive and data-scarce field of AI-driven life sciences.

The new firm’s structure is intentionally lean, eschewing associates and leveraging proprietary AI agents for its day-to-day operations. This allows Pande and Werner to focus their efforts on a small number of portfolio companies, primarily in AI for healthcare delivery and clinical trials. Pande stresses that a key lesson from his career is the primacy of a solid go-to-market strategy, which he argues is often harder to develop than the core technology itself.

VZVC's Concentrated Model

• Firm Name: VZVC (co-founded by Vijay Pande and Zach Werner)
• Annual Investments: Approximately five highly concentrated bets
• Team Structure: No associates; relies heavily on internal AI agents for operations
• Investment Focus: AI for healthcare delivery and AI for clinical trials
• Core Philosophy: Long-term partnerships with high-integrity founders, emphasizing that go-to-market is as critical as technology

Pande’s move highlights a persistent challenge in AI for medicine: the data bottleneck. Unlike text-based models that can be trained on the open internet, biological data is expensive to generate and typically remains proprietary. This creates 'walled-off' datasets, slowing industry-wide progress. Pande suggests the field is moving toward building foundational 'atlases' of biological information, similar to open-source LLMs, which could democratize access and help AI models connect insights across specialized medical fields that human doctors often can't.

Vijay Pande’s pivot from a mega-fund to a concentrated model underscores a critical market reality: in the high-stakes, data-scarce world of biotech AI, a brilliant algorithm is no longer enough. The new competitive frontier is defined by superior go-to-market strategies and access to proprietary, high-quality data, making deep founder partnerships more valuable than a sprawling portfolio.